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Abstract: There are over 2.6 million users of e-cigarettes in the United Kingdom1 
alone as they have been promoted as safer alternative to traditional cigarettes. The 
addition of flavours and aromas has also proven to be popular with younger 
generations. In this review we survey the range of studies in the short timeframe 
since e-cigarettes reached the market to draw attention to the health associated risks 
and benefits of its introduction. We complement this review with a case study 
reporting on the composition of selected e-cigarette refills with particular emphasis on 
the toxicological activity of its components on lung cells.  
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 Background 
Electronic cigarettes (e-cigarettes, e-cig or personal vaporiser (PV)) are battery-
powered devices that deliver vaporised chemicals to the user with sales over $1.7 
billion for 20132, currently there are over 7,500 flavour variations3. They may contain 
nicotine alongside other chemicals, such as flavourings and enhancers, while some 
variants may contain tobacco extracts4. The key differences between conventional 
and e-cigarettes are that e-cigarettes do not usually contain tobacco5 and smoking 
conventional cigarettes leads to the combustion of tobacco products. The process of 
heating in e-cigarettes is gentler than in conventional cigarettes5. Several studies 
clearly show that e-cigarettes vapours have less combustion products than the ones 
produced by regular cigarettes, many of which are carcinogenic5, though new 
manufacturers are increasing the heating temperature to allow for a more “real” 
effect6. As 30% of the cancer deaths in USA are caused by tobacco, and from this 
more precisely the tar component is the killer7,8 it is understandable e-cigarettes (with 
no tar available) are being branded a safer alternative to tobacco. 
E-cigarettes are composed of: a cartridge or tank which is used to store liquid 
material containing the “e-liquid”, “e-juice” or “nicotine solution”9. The cartridge serves 
as a reservoir of storage for the liquid and also acts as the mouthpiece of the e-
cigarette. A heating element is used as an atomiser to turn the liquid into a vapour10, 
and a power source such as a battery, which can be either manual or automatic, 
make up the rest of the device. The vapour is only produced while the heating 
element is activated and not between puffs. The vaporised liquid condenses into an 
aerosol, later inhaled delivering nicotine, vehicle and flavourings9,11. The vapour is 
generated by heating the solution to temperatures ranging from 65°C to 120°C, with 
a reported maximum atomiser temperature of approximately 250°C9 increasing the 
chances of carbonyl formation. Different models are available with some more 
manual type to control the delivery and temperature12. Propylene glycol and glycerine 
are used as carrier with the first one being the more widely employed, even though 
glycerine has been used in traditional cigarettes13. The vapour can contain carbonyl 
compounds like formaldehyde, acetaldehyde, and acrolein, which have been shown 
in numerous studies to be toxic. Formaldehyde and acetaldehyde are classified as 
carcinogens14,15 and acrolein as irritant16. 
E-cigarettes are sold as a healthier option to tobacco smoke and physicians are 
currently asked their opinions in this area17 . Furthermore around 95% of the general 
population believing them to be healthier18. So far the research has proven the e-
cigarette vapour is not benign, but less hazardous than traditional cigarettes17. E-
cigarette users commented in open forums in internet account for side effects of 
users such as headaches, respiratory tract irritations and digestive problems17. 
Clinical studies has shown only 10% of traditional smokers quit smoking after 
switching to e-cigarettes, but the biggest change was observed in the reduction of 
traditional cigarettes per day in favour of e-cigarette puffing18. On the pro e-cigarette 
side, the hypothesis postulates the absence of the tar products, pyrolysis and lower 
plasma nicotine content (around 10% of the tobacco cigarette) would make it a 
healthier option for traditional cigarette smokers. A clinical study has also shown that 
cell blood counts and marker are statistically not affected upon exposure of e-
cigarette users and passive user. On the contrary, the exposure of tobacco cigarettes 
(users and passive users) shown marker of inflammation after 3 hours19. 
However, there is conflicting information regarding the risks posed to public health 
and the health benefit from e-cigarettes. The Consumer Advocates for Smoke-free 
Alternatives Association (CASAA), has reported a significant risk reduction when 
assessed against regular cigarettes20. However, groups of studies indicate that e-
cigarettes may produce long-term and short-term side effects, such as airway 
resistance, irritation of the airways, redness of the eyes and drying out the throat21-23. 
Research has been focused on the toxicological aspect of e-cigarettes on lung, heart 
and cancer2 while some reports might have inconsistencies or conflict of interest, 
though the general view directs towards a more toxic effect24. The World Health 
Organisation (WHO) and the Food and Drug Administration (FDA), have indicated 
the safety and the potential health damage of e-cigarettes and its constituents have 
not been fully studied and so remain undetermined10,25. Guidelines form the FDA 
indicate an inclination towards the enforcement if the same rules applying to 
traditional cigarettes for the term of sales and marketing strategies of electronic 
cigarettes2. 
The majority of the research has been divided as: i) analytical assessment of the e-
liquids, ii) analytical assessment of the vapour phase, iii) toxicity of the e-liquids 
and/or vapour in animal models and/or animal cells, iv) toxicity of the e-liquids and/or 
vapour in human cells (primary and immortalised both cancer and non-cancerous, 2-
dimension and 3-dimension) and v) clinical studies on cigarette (traditional and/or e-
cigarettes) smokers. Though the analytical assessment seems to be more 
reproducible due to standardising methods used in the chromatographic method, 
eluents, detection; more variability appears in the biological work, this might be 
related to the dosing, concentration of ingredients, sample variation from same or 
different manufacturers, flavourings, cells and even different cell culture media used 
to feed cells. 
Composition 
Tobacco smoke comprises many classes of chemicals including polycyclic aromatic, 
alkaloids (such as nicotine), hydrocarbons, benzo(a)pyrenes26. The green leaves of 
the tobacco plant are almost entirely free of the dangerous tobacco specific 
nitrosamines (TSNA) such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), 
and N'-nitrosonornicotine (NNN); during the post-harvest process (known as curing) 
these TSNA are formed when the natural occurring alkaloids are nitrosated; these 
chemicals then during the cigarette burning can enter the respiratory system27,28. 
There is a wide difference in the content of TSNA in different tobacco brands, 
implying different plant sources, curing and purifications process29. E-cigarettes do 
not have a source of combustion, this is a reason why the health risks of vaping are 
assumed to be less harmful compared with traditional smoking. Therefore 
manufacturers have shown a growing interest to produce e-cigarettes, for indoor use, 
whereas the traditional cigarettes have been banned20,30. Nevertheless some studies 
indicate, in general, the components in the e-cigarette aerosols and e-liquid refills 
contain: the carbonyls formaldehyde (up to 9.0 µg/g of e-liq), acetaldehyde (up to 
10.2 µg/g of e-liq), acrolein (up to 5.5 µg/puff), propionaldehyde (up to 1500 ng/puff); 
the Volatile Organic Compounds (VOCs) toluene (up to 6.3 µg/150 puff), N-
nitrosonomicotine (NNN) (up t 16.7ng/mL e-liq), 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone (NNK) (up tp 10.8ng/mL e-liq), glycols such as propyelene glycol and 
glycerine (variation), nicotine (depending on the manufacturer’s label), traces of 
polycyclic aromatic hydrocarbons and the metals Ni (up to 0.29 µg/150 puff), Cd (up 
to 0.22 µg/150 puff) and Pb (up to 0.57 µg/150 puff) with traces of Ag, Al, Zn and Cr 
18,31. 
Nicotine. From vapours containing tobacco, tobacco specific nitrosamines (TSNAs) 
including N’-nitrosonornicotine (NNN) and 4- (methylonitrosoamino)-1-(3-pirydyl)-l-
butanone (NNK) can be formed in the combustion process in traditional cigarettes32 
and are considered to be highly toxic33,34. There is evidence these toxic carbonyls 
compounds have been found in the vapour of e-cigarettes35. Some studies have 
demonstrated that impurities and nicotine degradation products such as nicotine-cis-
N-oxide, nicotine-trans-N-oxide, myosmine, anabasine, and anatabine, which are 
very carcinogenic, can be found in e-cigarettes refill liquids36. The molecules can lead 
to mutations in genes such as Ras (vital function in signal transduction of cell 
proliferation), p53 and Retinoblastoma (with roles as tumour suppressors) as these 
molecules can form adducts with cellular DNA37-40. Nicotine can be absorbed through 
different routes such as: inhalation, ingestion, skin, and mucous membranes, 
therefore it is feasible he vapour from e-cigarettes users could cause secondary 
exposure of nicotine and other toxins to the individuals in the surrounded area26. 
Nicotine is a stimulant and side effects can include death, a danger of e-cigarette 
refills are for those bottles containing fruity or sweet flavours and aromas for which 
children can mistake them for fruit juices; a fatality on a 2 years old child after 
drinking an unknown amount of e-cigarette refill has been reported12. Concentrations 
of nicotine in the air have been studied for conventional and e-cigarettes. It has been 
reported that e-cigarettes with a refill liquid of nicotine concentration of 24 mg/ml 
emitted nicotine concentrations between 0.82 μg/m3 to 6.23 μg/m3, with the mean 
concentration of nicotine from regular cigarettes ten times higher (31.60 ± 6.91 
μg/m3) 41,42 . A threshold limit of nicotine exposure in the work place is published by 
The American Conference of Governmental Industrial Hygienists established a limit 
of 500 μg/m3 for an eight-hour time-weighted average (TWA)43. Manufacturers 
indicate the expected level of nicotine in the e-cigarette refills, though they are very 
close to the label value, though some samples seem to not reflect the label value32, 
we observed in our studies that provenance of nicotine is also an important factor. 
Nicotine can be used in the chemical industry and this grade of nicotine is not as 
pure as pharmaceutical nicotine which should be employed in the tobacco industry. 
Alkaloids are present in plants and one of the most notorious examples is nicotine, 
other alkaloids from tobacco can include cotinine, myosmine and anabasine with 
them being present in e-cigarette refills. A comprehensive study on the alteration of 
gene expression on CCL-185 (human lung carcinoma cell line) upon exposure to 
these four alkaloids44 showed up-regulation of CEACAM6 (adhesion molecule 
involved in carcinogenesis and metastasis) when the cells were treated with nicotine 
and myosmine and decreased when exposed to anabasine and cotinine. In the case 
of ALDH3A1 (an enzyme involved in the detoxification of reactive aldehydes), the 
treatment with myosmine showed upregulation while for PIR (transcription regulator 
for apoptosis and oxidative stress) was down-regulated in the cases of nicotine, 
anabasine and cotinine while mysomine had little effect. Only nicotine showed up-
regulation of TLR4 (ligand involved in the immune response) while the other 
compounds showed a decrease thereof44. 
Various metals such as metals like nickel, cadmium, lead and silica particles can be 
present in the aerosols produced from e-cigarettes, they could arise from the wick 
and heating coil constituents, these are considered to be carcinogenic, nephrotoxic, 
neurotoxic, and hemotoxic45.  
Glycerine (glycerol) and propylene glycol. Glycerine, is an intermediate in 
carbohydrate and lipid metabolism. It is used as a solvent, emollient, pharmaceutical, 
and sweetening agent in food industry46. Both glycol and glycerine are used in 
manufacturing industries as well as aviation and are well knowns respiratory irritants 
(Callahan Lyon). Glycerine and propylene glycol are chemical compounds both used 
in normal and e-cigarette liquids to control the moisture content47. However, they may 
be pyrolysed (burned) to acrolein and formaldehyde at higher temperatures15. 
Acrolein and formaldehyde have been found in e-cigarette vapour even though, the 
levels detected were 15 times smaller than conventional cigarettes. This is due to the 
fact that the evaporation temperature of e-liquids at 100oC-250oC48 is lower than that 
of the combustion temperature of up to 650oC in regular tobacco cigarettes49, 50.  
Flavourings and their toxicities. The sensation of flavours is determined by chemical 
substances that can interact with the senses of taste and smell51. There are over 
2,500 individual flavouring substances being employed in the food industry. Safety 
procedures have been introduced to control their use52, though they are directed to a 
consumption through food rather than e-cigarette, where the uptake is different. In 
general, through oral consumption, quantities in the food need to be considered and 
these chemicals (aldehydes, esters, acids) tend to be metabolised very rapidly 
through active enzymes in liver and intestine (Phase I and Phase II enzymes, 
including the CYP450 family and glutathione transferase)52. A decision tree is 
followed based on the chemical structure and concerns on data from human and 
animal studies. The Flavour and Extract Manufacturers Association (FEMA) assess 
the safety of chemical compounds used as flavouring ingredients but cannot regulate 
the use the flavour ingredients in e-cigarettes, as the use of the flavourings in e-
cigarettes has not been approved53. Some anti-tobacco groups claimed the addition 
of flavours to traditional cigarettes could attract new smokers; different flavours can 
be added from oils to natural extracts with majority of them in the fruity range such as 
mint and menthol; in the case of traditional cigarettes the combustion temperature 
could produce pyrolysis or oxidation of these compounds converting them into toxic 
carbonyls54. There is often no more information given about the composition or 
source of such additives, other than that, these flavours are “natural“20. As the most 
widely available sources of flavourings are for food products, we could expect some 
of the e-cigarette manufacturers could be using food flavouring products. For 
example, diacetyl (butanedione or butane-2,3-dione) is a by-product of the 
transformation of glucose to ethanol by yeast during the beer fermentation process 
and is extensively used in the food industry giving flavour to dairy products55. It is 
safe as food flavouring in popcorn, but when inhaled it has been shown to produce 
“popcorn lung syndrome” or bronchiolitis obiliterans56. Animal studies of diacetyl 
exposure have shown morphological changes in the liver55 and studies of cells 
exposed to butterscotch flavoured e-cigarettes have also shown toxicity21.  
Menthol is one of the most widely used flavours in both e-cigarettes and traditional 
cigarettes. These mentholated (e)-cigarettes seem to mask some early signs of 
respiratory diseases as menthol has antitussive properties. Nevertheless this seems 
to be more a hypothesis than real data57 and very limited information of toxicological 
data is available even on traditional cigarettes58. Menthol is a volatile compound and 
it could be ready vapourised rather than suffer pyrolysis. As a food additive, menthol 
has been subjected to much toxicological research but little has been done on the 
respiratory tract with very little findings besides irritation in vivo, even though menthol 
is present in many products directed to treat respiratory problems such as the case of 
Vicks Vaporub.  
An interesting study59 on an adenocarcinomic human alveolar basal epithelial cell 
(A549, a cancer cell line, generally used for anticancer drug screening safety profiling 
of new drugs) showed that exposure of vapours of several flavouring agents, 
cinnamladehyde, benzaldehyde, diacetyl, 2,3-pentadione, vanillin, acetoin and 
triacetin, for 24 hours proved to be very toxic on the cells; especially on the cases of 
cinnamaldehyde and benzaldehyde. This is in accordance with other studies in 
where cinnamon flavour in e-liquids has shown high cytotoxicity levels in other 
cells34. Interestingly, vanillin, acetoin and triacetin proved to be the less toxic. Another 
study employing the same cell line but challenged to different varieties of e-liquids 
found no toxicity though there was an increased level on the release of IL-860 only at 
a very high dose.  
Immortalisation of human cells using telomerase or SV40 virus are good option for 
cytotoxic studies. In the case of bronchial cells, some examples are Beas-2B and 16-
HBE14o. A study testing individual flavours for chocolate (2,5-dimethypyrazine), 
vanillin, apple/citrus (damascenone), floral (linalool), raspberry (α-ionone), sweetener 
(ethyl Maltol, generally used for candy floss, caramelised sugar) and strawberry 
furaneol challenged the cells for 24 hours. At the concentrations tested findings 
shown vanillin and furaneol were relatively non-toxic (agreement of vanillin with other 
studies59. The rest of the flavours showed activity on the cells while the chocolate 
flavour shows a reduction of the capability of producing/communicating signalling 
molecules3. 
As the e-cigarette industry is growing, more needs to be done to assess the quality of 
the ingredients as well as the biological effect. Many groups compare both the 
analytical composition and the toxicological effect of the e-liquid and the vapours 
associated with it61,62. The different temperatures that can be achieved in the 
vapourisation chamber (up to 350°C) can modify the functionality of the chemical 
ingredients transforming them into dangerous carbonyls such as formaldehyde and 
acetaldehyde. Their concentration in the vapour seems to be dependent on the 
voltage and temperature62, nevertheless the amount of nicotine found in the aerosol 
has been found to be 85% lower than traditional cigarettes63 implying the smoker and 
passive smokers of e-cigarettes are exposed to less damage.  
A very interesting decision tree for carcinogenicity, mutagenicity and teratogenicity 
for flavourings proposed by Costigan61 highlights the need to compare both what the 
seller informs about the ingredients and their quantities with the results from the e-
liquid and breakdown products employing GCMS. From here the ingredients can be 
compared to existing data base for biological information. If more and/or new 
ingredients are found then they will need to be assessed. 
Analytical method of assessment 
Gas-chromatography coupled to mass spectrometry, GCMS, is the most popular 
method for analytical detection in majority of the articles revised. Another variants 
include gas chromatography coupled to thermal energy analysis (GCTEA) which is 
very sensitive to nitrosamines63 and liquid chromatography with tandem mass 
spectrometry (LCMSMS). Each technique has benefits and disadvantages. The 
ingredients in the e-liquids are volatile compounds and some e-liquids have a simple 
formulation (single flavouring agents, propylene glycol, nicotine) and some have 
complex mixtures (natural extracts for flavour, sweeteners, tobacco and more). GC 
relies on the volatility of each chemical and when this is not possible a process of 
derivatisation can be added. LC on the other hand, does not require the compounds 
to be volatile but to dissolve in the elution system, generally using acidified 
water/methanol or water/acetonitrile with the pH modified to aid separation and 
ionisation. Columns used in both methods are generally based on C18 for LC64, polar 
column such as HILIC have been very useful and polysilane for GC65. We found 
some compounds such as menthol are not detected very well in LCMS though it is 
easily observed using GCMS. The tandem quadruple MSMS or time of flight ToF 
allows for quantification if a patron was used for compound monitoring (optimisation 
technique that works as a fingerprint). Limits of detection and sensitivity apply to all 
techniques as well as accuracy63. Some groups have used both GCMS and LCMS 
but for different purposes66. For example GCMS for the analysis of 
solvents/humectants (propylene glycol and glycerine) and polycyclic aromatic 
hydrocarbons; and LCMS for the quantification of nicotine, nitrosamines and flavours. 
From the review data, there is no “one fits all” but more modern equipment seems to 
perform better than some of the older techniques. Infra-red (IR) technology can 
detect the functional groups in small molecules, and can differentiate if in a sample 
there is a carbonyl, a hydroxyl or a nitrile group. New and more sensitive equipment 
using IR is emerging and allowing for the use on the cosmetic, food, and forensic 
industries67-70. Techniques like Attenuated Total Reflectance – Fourier Transform – 
IR (ATR-FT-IR) and near IR (NIR) alongside modelling methods  like K-nearest 
neighbours (k-NN), partial least squares-discriminant analysis (PLS-DA), soft 
independent modelling by class analogy (SIMCA), classification and regression tress 
(CART) and randon forests with Matlab as data processing software have been 
wisely used to determine if an e-liquid has nicotine or not67. 
Heating propylene glycol can produced the toxic carbonyls formaldehyde (600°C), 
acetaldehyde (600°C),  and acrolein (traces at 350°C)16. A free-radical dehydration of 
glycerol yields 3-hydroxyl-1-propen-1-ol and through tautomerisation 3-
hydroxylpropionaldehyde can be formed; the latter one can lose one water molecule 
through free-radical formation to give rise to acrolein71. If the temperature is >400°C, 
3-hydroxylpropionaldehyde can be converted to formaldehyde and acetaldehyde by 
retro-Aldol reaction71. An interesting study71 trapped aerosols at different vapour 
conditions and monitored the formation of aldehyde by means of trapping with 2,4-
dinitrophenylhydrazine and assessing by HPLC-UV. The coil in the electronic 
compartment will heat the e-liquid when power is applied, this is measure in watts. It 
is noticeable that different electronic designs produce a different output. While some 
designs produce a steady increase in the three aldehydes when more power 
(producing more temperature) is applied, in some other cases the amount remains at 
low level and with no increase. 
Metal content is a known issue in traditional cigarettes and traces of metals have 
bene found on e-cigarettes, ICP-MS methods have also been used to assess the 
heavy metal content in e-liquids72. 
Health 
E-cigarettes are getting more widely used due to promotion of manufacturers as a 
healthier alternative to conventional smoking. Amongst the complaints e-cigarette 
users describe, mouth and throat irritations have a higher incidence, this could be 
due to carbonyls formed during vaping16. It is important to notice that burns are also 
important consequences from the electronic devices due to faulty or fake batteries 
and/or mechanisms73.  
Other volatile organic compounds (VOCs) such as toluene and m,p-xylene which can 
be produced in the process are considered to be carcinogenic, hemotoxic, neurotoxic 
and irritants19. More harmful side effects are continuously being found19, 74-78 through 
in vitro and animal models. The vapour heating process can produce carbonyls, 
though in not as high concentration as traditional smoking. Tthere is biological 
evidence that aldehydes are toxic to mammalian cells by acting as mutagens, 
producing DNA single-strand breaks and chromosomal aberrations79. Toxicity comes 
in different shades, in the case of human and animal subjects, toxicological studies 
imply the assessment of biomarkers such as pro-inflammatory cytokines, 
development of cancer, teratogenicity, plasma nicotine concentration and effect on 
metabolism80-82. For animal models a lethal dose can be assessed. In the case of cell 
culture, toxicity initially appears as cell viability to then follow cell health, metabolic 
pathways, mutagenicity, release of cytokines and signalling81,82. Studies in mice, 
which are indicators of acute exposure due to high concentrations and short but 
persistent contact with the vapour, have shown an increase in inflammation markers 
such as IL-6, IL-1α and IL-13 especially in the lung area83 and reduction in immune 
defence towards bacterial and viral infections as the phagocytosis by alveolar 
macrophages was compromised upon challenge with e-cigarette smoke84. In the 
case of rats80, e-cigarettes with nicotine affected the body weight and energy intake, 
alteration in the lipid profiling (though some effect was observed when nicotine was 
not present). Nevertheless with or without nicotine, the e-cigarettes depleted the 
hepatic glycogen producing hyperglycaemia and affected the kidneys by altering the 
anti-oxidant response in both cases with or without nicotine, implying the rest of the 
ingredients have toxicological effect on renal ducts81, 82. 
Though research on e-cigarette toxicity is not very extensive the area is not free of 
controversy as the market is relatively new. Several studies have been carried out on 
human and animal cells, animal models, stem cells and some short clinical trials, 
using vapours, smoke extract and similar obtained from e-cigarette devices as well 
as the e-liquid refills83. There is an increasing amount of research dedicated to the 
toxicity of the contents of the e-cigarette refills, looking at the biological activity of 
nicotine, vehicle and flavours76,83,85. Studies on human bronchial airway epithelial 
cells and human foetal lung fibroblast showed that challenge with different flavours of 
e-liquids83] exhibited high levels of stress in the form of reactive oxidative species 
(ROS) and the cell morphology changed to enlarged cells; as well as decreased cell 
viability and raise of inflammatory markers and response in neutrophils21,83,86. 
Published research is trying to shed light on the hot topic “are they toxic” so more 
studies are focusing on comparing e-cigarettes to tobacco cigarettes. In a study 
comparing both types of smokes on HaCat (non-cancerous human keratynocytes) 
and A549 found that pro-inflammatory cytokines and chemokines (PDGf-BB, basic 
FGF, IL-8, IL-12, IL-17, GM-CSF, IP-10, MCP-1, MIP-1β in both cells and IL-1rα, IL-
10, G-CSF, IFN-γ, RANTES, TNF-α and VEGF in HaCat) were released upon 
exposure to e-liquids with cell death more preponderant in the traditional tobacco 
smoke87. 
A great majority of the biological studies focus on the lung and cardiovascular 
functions and morphology with the nasal epithelia being overlooked. A study 
conducted on this topic, collected biopsies and fluids from nasal passage from non-
smokers, cigarette and e-cigarette smokers88. The changes in the expression of 
mRNA of keys genes was used to monitor the health of the cells and the metabolic 
pathways. The findings include a decrease in the expression of immune related 
genes for electronic and traditional cigarette smokers and in some cases the 
response was stronger in e-cigarettes, indicating this type of smoking changes the 
immune composition at the nasal mucosa. A review by Biyani focus on the area of 
otorhinolaryngology89 looked at the implications of e-cigarettes in the paediatric clinic 
as 80% of adult smokers started smoking before reaching 18. Though they did not 
present any clinical trials to determine the effect of passive e-cigarette smoking, they 
presented the problem of liquid poisoning (as small children believe then bottles to be 
fruit juices) and young adults commence to smoke believing e-cigarettes to be non-
toxic. 
A decrease in cardiovascular function has been linked to the use of traditional 
cigarettes, with the main side effect being inflammation, thrombosis and oxidation of 
low-density lipoprotein that can affect the myocardial activity4,88,90. A clinical study 
sponsored by the Lorillard Tobacco Company, using human subjects compared to 
traditional cigarettes91, with both limited exposure (for standardisation, 1 refill of 
16mg/mL providing 50 puffs vs 1 Marlboro® Gold King size with both yielding around 
0.8mg, though in real subjects this might vary). Unlimited exposure found the nicotine 
plasma level to be increased (with the traditional cigarette being higher 
concentrations and faster at 5 minutes), also the combination of propylene glycol with 
glycerine in the e-liquid helps to deliver more nicotine than propylene glycol alone. 
The mechanism for heart rate due to nicotine has been elucidated and described by 
the activation of the sympathetic nervous system with release of norepinephrine and 
epinephrine upon incorporation of nicotine92-94. As the traditional cigarette peaked 
nicotine in plasma higher and faster than the e-cigarette, the heart rate was 
increased in correlation to the amount of nicotine in plasma, with this being higher 
than the traditional cigarette91. Though the e-cigarettes shown to increase the 
nicotine content in plasma, affect the systolic & diastolic blood pressure and increase 
the heart rate, they were at lower values than traditional cigarettes, with them being 
clinically insignificant at the conditions used. Other studies seem to validate the 
notion that switching from traditional cigarettes to e-cigarettes (and hopefully then 
quitting completely) will assist to lower the systolic blood pressure93,95 and some of 
them finding the nicotine plasma level to be equal in both e-cigarette vs traditional 
cigarettes96.  
More recent studies are using different systems to assess toxicity, such as a C. 
elegans model97, in which refill components (nicotine, propylene glycol, flavourings) 
were tested; oxidative stress, growth and brood size were affected the same way 
when tested at both liquid and vapours. 
It is important to note that many of the studies arrive to the same conclusion 
regarding the biological activity as well as the analytical composition but parallels are 
difficult to be drawn amongst the many different studies as concentration of the 
dosing sample varies as well as conditions (such as feeding media, time and type of 
exposure) presented in the literature. An excellent review published in ATLAS98 
comments on majority of the in vitro methods used (2D, 3D) and different types of 
assays to study toxicology, risk assessment, cell transformation and cell health 
assays and genomic analysis of tobacco products; they could be extremely important 
when planning biological research. 
Marketing and metrics 
With a world-wide market reaching over £35 billion by 20257,8 not much emphasis 
can be found on the marketing e-cigarettes receive, but a presentation by Monks and 
Crawford (Texas Tech University Health Sciences Center, El Paso) obtained in the 
USA Environmental Protection Agency website73, provides some interesting 
numbers. In the UK figures obtained from Action on Smoking and Health (ASH) 
showed e-cigarette users numbers rose from 700,000 in 2012 to 2.1 million by 20148. 
For 2014, in the USA, around 3.9% of this population (450,000 early teens) smoke e-
cigarettes, with 13.4% (2 million) teens smoking them. This highlights the growing 
tendency into this habit; on the other hand this teen population fell from 15.8% of 
tobacco smokers to 9.2% by the same year7,8. As this overall population is under 18, 
and banning laws apply, more disguises (tic-tac boxes, juice bottles) are found for the 
e-cigarettes to be smoked. Calls related to e-cigarette poisoning in the state of Texas 
showed that 57% was related to children younger than 5 years old. There were 
unintentional with 96% in their houses, 85% was from ingestion and 11% dermal. 
This is an important aspect as the marketing directed to adults is also affecting small 
children. The e-cigarette marketing has been very aggressive, many of them with a 
strong sexual content, or trying to relate to foods/diets or traditional cigarettes as well 
as using celebrities; for this the advertising expenses have increased from $6.4 
million in 2011 to a staggering $112.9 million in 201473. 
In this review we screened the web for information on the composition and toxicity of 
e-cigarettes, with an emphasis on the flavours activities and health profiles. Analytical 
studies have shed light in the complex composition of the e-cigarettes, in where 
flavouring additives how an unknown effect on the delicate lung epithelia. We present 
a case study, we used LCMSMS to assess the analytical content of a group of e-
cigarette refills compare our results with publish data, not surprisingly our results are 
in agreement with other groups while using similar analytical techniques. In this case, 
we also studied the biological activity of these e-cigarette refills ingredients in a 
normal cell line representative of human lung epithelia. To make the case study more 
relevant to the wide variety available in the market, we selected different branded e-
cigarettes with different flavours, with and without nicotine. In accordance with the 
majority of the published research available, we also found the refills to be toxic to 
the cells, with some being less toxic and some allowing the cells to recover after the 
challenge. For this case study, we purchased around 18 samples of e-liquids and 
challenged the human bronchial cell line Beas2B to different concentration of the e-
liquids from 1 day to 3 days of exposure.  
 
Materials and methods 
Materials. Thermo Fisher Scientific, Altrincham, Greater Manchester, UK: 0.25% 
Trypsin-EDTA (GIBCO), sterile phosphate buffered saline, acetonitrile optimal LCMS 
grade (ACN), ammonium acetate analytical grade, formic acid optimal LCMS grade. 
Lonza, Slough, Berkshire, UK: BEGM Single-Quot kit. Sigma-Aldrich, Dorset UK: 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), sterile phosphate 
saline buffer (sPBS), nicotine, propylene glycol, dimethyl sulfoxide (DMSO), 
chlorpromazine. ECACC, Porton Down, Salisbury, UK: Beas2B cell line 
(immortalised cells obtained from autopsy of normal human bronchial epithelia from 
non-cancerous patients). VWR West Sussex, UK: plastic ware. Anachem, Luton, UK: 
pipettes and pipette tips. Amazon UK: e-cigarette refills. Superdrug, Manchester, UK: 
Nicolite refills. Hichrom, Reading, Berjshire, UK: 0.2µm polypropylene syringe filters. 
Cell maintenance. Cells were grown as adherent monolayer culture in 75cm2 flasks in 
Bronchial Epithelial Growth Medium (BEGM) using Lonza’s BEGM SingleQuot kit, at 
37°C, and under a humidified atmosphere containing 5% CO2 and 95% air. Cells 
were passaged twice a week after reaching 70% confluence. 
MTT assay. Two types of e-liquids are available on the market, synthetic, containing 
artificial flavours and natural, containing extracts of tobacco leaves and natural 
flavours extracted from plants. Pre-packed cartridges can have varying nicotine 
concentrations (ranging between 0-18 mg/ml nicotine/cartridge) with diverse 
flavourings for example tobacco, menthol, mint, chocolate, apple, cherry, caramel 
and many more (12,13). We used different suppliers that were commercially 
available over the counter and through the internet. We tested a variety of flavours 
and nicotine content; as well as synthetic nicotine and propylene glycol which is used 
generally as carriers for the production of the vapours. All e-cigarette refills, nicotine 
and propylene glycol were tested at a range of concentrations (0, 4, 10, 20, 40, 80, 
120, 160 and 200% puff, with each puff being 5 µl (100%) for e-cigarettes with 
dilutions in sterile water, 0-1.64mg/ml for nicotine stock, 0-0.1g/ml for propylene 
glycol stock, 0-100 µM for chlorpromazine (this is the positive control in all assays). 
Cell death percentage was determined by the colorimetric MTT [3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] micro-culture assay. Cells were 
detached from the 75cm2 flasks (at a confluence of 70%) by trypsinisation, seeded in 
100μl aliquots into 96-well clear micro-culture plates. Cell densities of 40,000; 30,000 
and 20,000 cells/ml for 24, 48 and 72 hours of incubation respectively, this method 
was chosen in order to ensure exponential growth of untreated controls throughout 
the experiment. Cells were allowed to adhere into the 96-well micro-culture plate for 
24 hours prior dosing. Stock solutions of the test compounds in water were 
appropriately diluted in complete culture media to make up the required 
concentrations, and then added in 10μL aliquots into the 96-well micro-culture plate, 
cells were exposed to the test compounds for 72 hours. Plates were maintained at 
37°C in a humidified atmosphere containing 95% air and 5% CO2. At the end of the 
incubation period 30μl/well MTT solution in sPBS (3 mg/ml) were added, then 
incubated for further 3 hours. After the end of the incubation, the supernatants 
containing medium and MTT were removed and the formazan crystals formed by 
viable cells which were dissolved in 100μl of DMSO per well. Optical densities at λ = 
540 nm were measured with LUMIistar Omega multi-mode plate reader (Edinburgh, 
UK). The colorimetric MTT assay was used to determine the cell death percentage at 
serial diluted concentration of the tested compounds and the concentration at which 
50% of cell growth was inhibited (IC50) as compared to the control wells which did not 
contain any test component was determined from a dose–response curve using 
OriginPro 9.1 (Northampton, MA, USA) data analysis and graphing software. 
Chlorpromazine was used as positive control in the MTT assay. Data were collected 
as duplicates and statistical analysis calculated as standard deviation (SD) using 
Excel Microsoft (Reading, Berkshire, UK). Pictures were taken with a microscope 
Axio Vert.A1, PE-300 from Zeiss, Cambridge, Cambridgeshire, UK. 
Mass spectrometry. The analysis was performed on Agilent 6540 LCMS-MS Q-ToF 
Jet Stream ESI (Greater Manchester, UK). Conditions: +2500V, CE (collision energy) 
80eV, Sheaf gas 350oC at 10l/min, drying gas at 325oC at 10L/min. Nebuliser gas 
pressure was at 18psi. The chromatography was performed on an Agilent 1260 
series (Greater Manchester, UK) with auto sampler and thermal controlled column 
chamber.  The separation was done on a Thermo Scientific Accucore HILIC 
50x2.1mm particle size 2.6µm (Thermo Fisher Scientific, Altrincham, Greater 
Manchester, UK) kept at a stable 20oC. The flow rate was set at 0.4ml/min using a 
gradient profile of ACN (acetonitrile) 95%:H2O 5% (0.1% formic acid / 5mM 
ammonium acetate) 0min: 100%. 20min: 60%. 25min 100% end 30min, with the 
remainder being H2O (0.1% formic acid / 5mM ammonium acetate). The column was 
prepped and stabilised for 6hours before running using ACN 95%:H2O 5% (0.1% 
formic acid / 5mM ammonium acetate with a flow rate of 1.0 ml/min. The samples 
were prepared by diluting the e-cigarette fluid 10µl with 990µl of ACN and filtered 
through 0.2µm polypropylene syringe filters (this can be known as “dilute and shot 
methodology”). 
Results and Discussions 
We tested 18 different e-cigarette refill flavours for their toxicity on human derived 
bronchial cells (Beas2B). In this case study aimed to confirm the literature results, we 
exposed the cells at different concentrations and times to the cells. The definition of 
“puff”, its volume and quantity seems to be different in various publications, as made 
with reference to the total reservoir and expressing it into nicotine content4,14,99,100. 
The puff is also dependant on the user, with some puffing a larger volume than 
others. Based on literature evidence of amount of nicotine used14,99,100 and the given 
value per cartridge of nicotine at an average of 18mg/ml, we calculated that 1 
inhalation might be equal to 5µl, and this “puff” would contain around 90µg of 
nicotine.  
Biological data 
In this work we will equate 1 puff to 5µl of the e-liquid refill. The Beas2B were 
exposed at 0, 4, 10, 20, 40, 80, 120, 160 and 200% puffs. This in effect means 0, 0.2, 
0.5, 1, 2, 4, 6, 8, 10 µl of refill respectively (dilutions were made with distilled sterile 
water). Exposure was for 24, 48 and 72 hours. The bronchus conducts the air into 
the lungs in where the surface area44 can varied in the range of 40-80m2. Although 1 
puff (5µL) appears to be a large volume, smokers rarely would have only 1 puff. 
Instead there would be a continuous flow; different groups might have a diversity of 
approaches to quantify the “puff”, nevertheless the main agreement seems to be 
centred on the amount of nicotine delivered. 
In Table I, we show the IC50 values obtained of duplicate results. At 24 hours, the 
IC50 values ranged from 1.12 to 70%, making some e-cigarettes based on menthol, 
tobacco and butterscotch flavours the most toxic ones (Figure 1). The same pattern 
seems to be repeating itself at 48 and 72 hours with ranges between 6.3-40% and 1-
92% respectively. Propylene glycol seems to show more toxicity when the cells were 
exposed at longer times (48 and 72 hours), while nicotine was quite consistent 
through the total study. Flavours like grape, blueberry, cherry and some menthol 
blends produced the lowest toxicity for the brands tested. 
To have a clearer understanding of the results, we plotted the IC50 values (Figure 1). 
It is interesting to note that at 24 hours the majority of the samples tested are very 
toxic with the IC50 values in the lower 1/3 band on the y axis, at 48 hours this 
tendency changes to be more in the middle band and at 72 hours there is a clear 
tendency for higher toxicity (lower band in the y axis). It is interesting to note the e-
cigarettes flavoured of vanilla and grape are the less toxic samples. Icemint can be a 
complex mixture and this can be observed in the increasing toxicity it showed on the 
cells. 
Pictures of each sample at dosages of 200, 120, 10, 4 and 0% puffs (a summary in 
Figure 2 and the remaining pictures and IC50 curves in the Appendix) were taken. In 
Figure 2, the pictures show the cells exposed to a low puff concentration (10% of 
puff) for the longest period of time (72 hours). 
In our set of 18 e-cigarette refill samples, we studied different fruit flavours as well as 
candy flavours such as butterscotch and bubblegum. The butterscotch flavour when 
inhaled has been found to be responsible for a particular lung condition in employees 
working in popcorn factories, called popcorn lung101. Exposure to diacetyl in the 
working environment affects the middle and lower airways producing cough, 
dyspnoea, and bronchiolitis obliterans102. This flavour has been discontinued in the 
market of electronic cigarettes, even though reports7 express concerns as this is 
found in around 75% of all e-liquids samples. Alternatives have been proposed (such 
as 2,3-pentadione, 2,3-hexanedione, 3,4-hexanedione and 2,3-heptanedione) and 
studied on murine models with results indicating they might not be completely 
safe103. The sample we obtained was shown to be very toxic, with IC50 values for 1, 2 
and 3 days of exposure around the value of 10% of a puff (0.5µL). The pictures 
clearly show how cell numbers are low and the cells are very elongated when 
compared to cells exposed to the media only. The other candy flavour, bubblegum, 
though toxic, had IC50 values in the range of 20 to 30% of a puff, with cell numbers 
higher and a slightly rounder shape. 
Vanilla is a popular flavour in sweets, we tested a vanilla refill, and we found the IC50 
values to be moderately toxic at 24 and 48 hours of exposure (~ 20%) and much less 
toxic at 72 hours (80%). This implies that the cells can recover with time if not 
exposed continuously, an indication of the possible health benefits of e-cigarettes. 
The cell numbers in the photographs (appendix) not only showed higher survival 
rates, but the cells were forming islands which is characteristic of lung type cells. 
Menthol and mint are very popular flavours, so we tested one sample of mint 
(icemint) and three samples of menthol. We found that the mint flavour was less toxic 
after 1 day of exposure (IC50 = 70%), but became more toxic the longer the cells 
were exposed (IC50 in the range of 30-20%). Furthermore, the cells also looked very 
unhealthy after the initial times of exposure, but showed remarkable recovery 
towards the 72 hour period of incubation, possibilities can include the cells managed 
to metabolise the toxic contents to less damaging agents. The menthol samples were 
in general very toxic with IC50 values for all incubation times lower than 20%. The 
cells looked to be elongated and in majority of cases quite isolated, it is interesting to 
notice that samples from different suppliers have different toxicity, giving rise to 
question what the ingredients are or at least the percentages in those refills. 
Electronic cigarettes, as a relatively healthier option, have much less ingredients than 
a tobacco based cigarette, and do not reach the extremely high temperatures of 
combustion. Nevertheless, because the tobacco flavoured e-cigarette is popular 
amongst consumers, we tested 4 samples of tobacco based e-cigarettes with 
different concentrations of nicotine. We found them all to be quite toxic, for example 
the classic tobacco flavour has IC50 values around 10%, and for tobacco with nicotine 
it was around 10-30% in a sample of virgin tobacco. It also became very toxic the 
longer the cells were exposed to the liquid. The cells looked much damaged at high 
concentrations and short exposure times, becoming very flat and elongated towards 
the end of the experiment. 
Fruit based flavours are very popular with younger generations. Suppliers might use 
natural or synthetic flavours to produce the desired flavour. From all the samples 
tested, except Dekang Cherry Blossom, they did not have nicotine in the ingredients 
list, this could explain why in general these samples were less toxic. We tested refills 
of flavours of banana, blueberry, grape, apple, strawberry and cherry. We found them 
to be moderately toxic (IC50 values in the vicinity of 30%), with the grape flavour 
being the least toxic one. Nevertheless, at high concentrations of refill liquid and 
short exposure times the cells look disperse, elongated and damaged. Towards the 
end of the trial, the cells looked healthier and forming some islands, thus showing 
better recovery. 
We tested a stock of nicotine and the propylene glycol carrier control. We found 
nicotine to be moderately toxic in the range of what it would be expected to appear in 
puffs (IC50 values between 15-30%). We also found that propylene glycol became 
increasingly toxic the higher the volumes of the puff and the longer the exposure 
times were (IC50 values between 5-15%). In both cases cells looked unhealthy with a 
tendency to recover. 
Interestingly a study performed on HaCat (normal human immortal keratinocytes), 
HN30 (human neck squamous cell carcinoma from a primary laryngeal tumour) and 
UMSCC10B (human neck squamous cell carcinoma from a metastatic lymph node) 
for which vapour of e-cigarettes with and without nicotine were tested found ~1.5 fold 
for samples without nicotine and up to 3 folds for samples with nicotine when DNA 
strand breaks were tested and increased cell death104. Extrapolating the results from 
in vitro to in vivo does not seem to be an easy subject, as there are many variabilities 
in the e-cigarette delivery due to different electronic devices, some research points in 
the direction of the nicotyrine hypotheses105. This chemical, product of the oxidation 
of nicotine seems to accumulate in e-liquids with time when it is exposed to air, it is a 
reversible inhibitor for CYP2A13 in the nasal and respiratory epithelia, and 
irreversible inhibitor of CYP2A6 n the liver. The hypotheses postulates that nicotine is 
delivered more effectible if nicotyrine is present as facilitates the absorption in the 
airway epithelia (by inhibiting CYP2A13) and inhibiting nicotine’s metabolism in liver 
(by inhibiting CYP2A6), therefore raising the nicotine’s plasma concentration and 
hence relieving the nicotine craving105. Though data seems to support it, more 
evidence needs to be acquired and a more complex approach needs to be taken 
which might not be able to be studied at single cell level. 
Analytical data 
We studied the 18 samples for their composition as well as nicotine content. Using 
state-of-the-art mass spectrometry equipment, we developed new liquid-
chromatography methodologies to test the ingredients and analyse the content of the 
main toxicant. An Accucore HILIC column was employed, and in it, nicotine showed a 
retention time of 7.55min, the sample was measured using MS/MS fragmentation 
163.1230m/z → 131.0650 m/z with CE of 30eV and a dilution curve with a highest 
amount of 25 mg/ml was prepared to quantify the areas related to the nicotine 
content. The results (Figure 3) showed for the samples which according to the 
manufacturer’s labels should be nicotine free had quantifiable levels of nicotine within 
them, majority of them had extremely low amounts in the low ppm (part per million) 
though some as butterscotch had 0.015% and juicy apple with 0.03%. On the other 
hand, the levels of nicotine in samples in which have stated nicotine content 
(manufacturer’s labels), vary depending upon the producer. The Nicolite branch, 
showed a large variation in the analysed to stated amounts, the 11mg/ml sample 
showed to be closer to 9mg/ml, and the 16 mg/ml samples that had different flavours 
such as tobacco and menthol, ranged from almost 6mg/ml to almost 12 mg/ml. The 
other manufacturers, Dekang and Vapouriz, for which the labels described a content 
of 18 mg/ml, showed a range of 16 mg/ml to 18 mg/ml. The levels of nicotine are 
likely indicators that GMP (good manufacturing practices) is not being followed by 
some manufactures of the e-cigarette fluids, and may run afoul of the current 
manufacturing guide lines set by the European Union106, it is interesting to notice that 
nicotine based e-cigarette refills showed the highest toxicity with IC50 values ranging 
from 3 to 25 % puff for the 72 hours period of incubation on the Beas2B cells. 
One of the most concerning flavour ingredient in e-fluids is the butterscotch 
flavouring, diacetyl flavouring (a diketone), (1.2min retention time)) which is known to 
produce lung disease when inhaled101,106,107. We analysed the AV Butterscotch 
flavour e-cigarette refills, and we found the content of diacetyl (presented a retention 
time of 1.2min) was 10.625 molecular count which in real terms means traces. This 
comes as good news for e-cigarette smokers, as other flavourings can be used to 
mimic the butterscotch flavour or aroma. Nevertheless in this particular e-cigarette 
refill sample, the biological data showed high toxicity in the biological assessment, 
implying the flavouring agent, maybe another member of the diketones family, is also 
toxic108.  
Tobacco flavours are extremely popular as it might give the e-cigarette smoker the 
sensation of a real cigarette but without the toxins. We investigated four samples of 
refills containing tobacco flavour and we found (Figure 5, the results are presented as 
molecular counts and they are actually traces in the low ppm of flavours only) they 
contain traces of several other chemicals including flavouring agents such as vanillin, 
ethyl butyrate (tropical flavour), ethyl vanillin, ethyl-methyl-maleimide (tobacco), β-
damascone (fruit), butanedione (butter) and benzyl alcohol (fruit). Investigation of the 
flavour profile of the tobacco flavoured e-fluids showed that it is posable to 
“fingerprint” the different manufacturer batches. While the number investigated was 
small it does open up the possibility of a data base for forensic analysis of e-cigarette 
analysis. Overall we found the e-cigarette refills contain around 99% of the carrier, 
with this being generally propylene glycol, up to 0.8% of nicotine (near 0% in the free 
nicotine refills), 0.018% sweetener (in the form of maltol / ethyl maltol and other 
sweetening flavours) and 0.002% of flavouring agents, including unknowns. It is this 
0.002% that would help to fingerprint a sample. Our data is quite in agreement with 
other studies636363636363[63] that have reported e-cigarette liquid to contain glycerol or 
propylene glycol ≥75%, water ≤18%, nicotine ~2% and flavours ~10%. This case 
study demonstrates that different approaches can reach to similar conclusions, 
though majority of the published research employs GCMS, the use of LCMS is 
equally valid. 
In our data, we also found all the samples from the brand Vapouriz contain 
dodemorph (as [M+H]+=282.2779), which is an antifungal109, all Dekang samples had 
the alkaloid sauroxine (as [M+H]+=275.2108)110, all Nicolite samples contain the 
alkaloid cytisine (as [M+H]+=191.1178)111 and all samples containing nicotine also 
presented the aromatic amine 1-naphthylamine (as [M+H]+=161.1069)112. From them 
only the latter one, 1-naphthylamine, has been found in traces in cigarette smoke113. 
Though it is uncertain the biological effect of these individual chemicals on the cells, 
we could not find a correlation between brands with or without the compounds.  
All the tobacco samples proved to be highly toxic with the Vapouriz ones presenting 
the highest cell death rate, incidentally the have less ethyl-methyl-maleimide though 
they have higher levels of vanillin based flavour. The small difference in the tobacco 
samples for the IC50 could be due to unknown ingredients in the refill, as many times 
manufacturers use natural or complex extras. 
In this case study we confirm the analytical composition and biological activity of a 
group commercially available e-cigarettes. By using LCMSMS we introduce another 
example of the benefits of employing this type of methodology, unexpectedly we also 
detected compounds that have been described before (dodemorph, sauroxine and 
cytisine) paving the way that more research is needed to elucidate the complex 
compositions. Cell viability is the method of excellence to screen, in a short time, how 
toxic a compound is, majority of the biological data published on e-cigarettes have 
used the same technique but on different types of cells. In this review we compared 
several biological matrices and we confirmed in this case study that e-cigarette refills 
are poisonous, some moderately and some highly toxic to lung cells.  
Conclusion 
Research by Action on Smoking and Health (ASH)1 showed e-cigarettes users has 
rapidly increased114 with the teenage group increasing 800%18, e-cigarettes are 
considered as one of the options helping people to quit smoking. However, the safety 
and reliability of e-cigarettes has to be reviewed extensively. Many of the literature 
reviewed, infer that e-cigarettes are not free of emission14-16,33,42,85,95,115 as they 
release an aerosol containing acetaldehyde, formaldehyde, nicotine, propylene 
glycol, glycerol and flavourings, with users and those who are exposed to second-
hand inhalation being affected19,75. Our work supports the opinion that e-cigarettes 
and especially the ingredients of the e-liquid, which can change in structure after the 
process of heating, have not been thoroughly characterised or evaluated for safety76. 
The evaluation of the results of this investigation supports our hypothesis that certain 
flavours of e-liquids, like menthol, tobacco and coffee are more toxic than others 
such as banana or apple, which shows less toxicity on Beas2B cells by direct liquid 
exposure.  
In a previous study the cytotoxicity e-cigarette refill samples using human embryonic 
and adult cells showed that majority samples were moderately to highly toxic to the 
embryonic cells, but less toxic on the adult cells. Also, the cytotoxicity was correlated 
to the other components of the fluids rather than the presence of nicotine76. In 
another study, the cytotoxicity of liquid (smoke) flavourings was assessed and 
compared it with that of cigarette smoke condensate. They found that cigarette 
smoke condensate were generally less toxic than liquid smoke flavourings on 
Chinese Hamster Ovary cells (CHO)77. Published results have shown in in vitro 
studies that human bronchial cells exposed to different e-cigarette vapours had 
mutations in the gene patterns similar to exposure to tobacco smoke116.  
The existing research does not indicate e-cigarettes are completely safe, even 
though the delivery of nicotine without the toxins found in tobacco cigarettes makes 
them a safer option. E-cigarette vaping is less toxic than smoking normal cigarettes, 
and this group of users benefit of this new technology. Nevertheless e-cigarettes 
contain toxicants including nicotine, flavourings and volatile compounds, and their 
thermal degradation products.   
We have clearly shown that flavours such as menthol, tobacco, and butterscotch can 
be considered toxic. However, the assumption that e-liquids with nicotine, especially 
with higher concentrations of 16 mg/ml, could be more toxic than the one without 
nicotine, could not be proven, this could be due to the complex mixtures of solvents, 
flavouring agents, sweeteners, enhancers and preserves. Nevertheless, e-liquids 
such as blueberry and tobacco are more toxic with a lower IC50-value then e-liquids 
with nicotine.  
Public Health England (PHE) has endorsed the use of e-cigarettes to help smokers 
to quit the habit117, evidence seems to indicate smoking electronic cigarettes is 
healthier than traditional tobacco cigarettes so for the traditional cigarette smoker this 
is a good option, especially if it allows quitting overall. But concerns have been raised 
for the passive smoker and the younger generations who find smoking e-cigarettes 
and exciting new habit24,73. Politics, policies and funding seem to play an important 
role in the evaluation of the safety of e-cigarettes and more independent, long-term, 
research needs to be obtained to determine how safe e-cigarettes really are24. 
The work reported in this review alongside a case study further contributes useful 
and new information to debate on the safety of e-cigarettes and the different 
flavouring liquids consumed by users in the devices, and clearly indicate some areas 
of concern which warrant closer attention in future, this in agreement with a recent 
clinical trial in where several toxicants biomarkers (nicotine and metabolites) from 
both traditional and e-cigarettes were monitored and shown the exposure was 
reduced upon switching17,18. 
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Table I: IC50 values of different e-cigarette refills tested on Beas2B at 24, 48 and 72 
hours. (Results for duplicate determinations). *: these samples do not contain 
nicotine. 1: (IC50 in µM, ± SD) 
IC50 (% of puffs, ± SD) 24 hours 48 hours 72 hours 
Aulola Butterscotch* 7.4 ± 5.2 10.1 ± 3.6 9.2 ± 1.7 
Vapouriz Bubblegum* 28.3 ± 0.6 26.3 ± 10.5 17.1 ± 2.1 
Vapouriz Vanilla Velvet* 25.5 ± 1.6 19.3 ± 0.9 79.0 ± 0.3 
Vapouriz Banana* 12.5 ± 1.7 39.8 ± 0.4 26.0 ± 0.9 
Vapouriz Grape* 32.7 ± 5.8 29.7 ± 9.7 91.6 ± 0.2 
Dekang CherryBlossom18mg/ml 20.9 ± 4.0 22.8 ± 1.8 24.7 ± 0.8 
Vapouriz Blueberry* 28.5 ± 1.8 12.3 ± 3.8 30.1 ± 8.8 
Dekang Blueberry Mist* 37.6 ± 0.1 24.5 ± 0.1 21.0 ± 1.1 
Vapouriz Strawberry Bliss* 20.8 ± 0.3 17.3 ± 0.1 18.2 ± 0.6 
Vapouriz Juicy Apple* 29.8 ± 6.3 21.5 ± 3.5 28.7 ± 0.6 
Nicolite Menthol 16mg/ml 8.7 ± 0.9 6.3 ± 2.6 2.8 ± 14.4 
Dekang Menthol 18mg/ml 21.7 ± 0.6 10.8 ± 2.4 12.3 ± 1.2 
Vapouriz Menthol Special blend 1.1 ± 1.6 18.4 ± 1.7 22.2 ± 4.1 
Vapouriz Icemint 68.9 ± 0.1 32.9 ± 0.9 19.3 ± 0.8 
Vapouriz Classic Tobacco 4.3 ± 7.3 9.5 ± 3.9 11.9 ± 6.5 
Vapouriz Virgin Tobacco 30.9 ± 5.8 15.2 ± 0.8 <1 ± 2.19 
Nicolite Tobacco 11mg/ml 21.9 ± 1.2 36.9 ± 0.3 11.5 ± 2.5 
Nicolite Tobacco 16mg/ml 31.0 ± 3.2 11.9 ± 14.7 24.7 ± 7.6 
Nicotine stock 18mg/ml 32.3 ± 1.5 27.2 ± 1.8 13.9 ± 2.9 
Propylene glycol stock 1g/ml 14.7 ± 5.4 9.5 ± 19.2 5.7 ± 2.2 
Chlorpromazine 1 3.1 ± 9.0 1.5 ± 4. 7 1.0 ± 0.2 
 
 
Figure 1: IC50 values at 24, 48 and 72 hours. 
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Figure 2: Cells exposed to 10% (0.1) puff for 72 hours: a: Aureola Butterscotch, b: 
Vapouriz Banana, c: Dekang Blueberry Mist, d: Vapouriz Juicy Apple, e: Vapouriz 
Bubblegum, f: Vapouriz Grape, g: Vapouriz Strawberry Bliss, h: Nicolite Menthol 
16mg/ml, i: Vapouriz Vanilla Velvet, j: Dekang Cherry Blossom, k: Vapouriz 
Blueberry, l: Dekang Menthol, m: Nicolite Tobacco 16 mg/ml, n: Vapouriz Virgin 
Tobacco, o: Nicolite Tobacco 11mg/ml, p: Vapouriz Classic Tobacco, q: Vapouriz 
Icemint, r: Vapouriz Menthol Special Blend, s: Nicotine stock (pharmaceutical grade) 
(0.08mg/ml), t: Propylene Glycol stock (0.005g/ml), u: Media 
 
Figure 3: Analytical determination of nicotine in the e-cigarette refills for which the 
nicotine content is 0 (zero) according to the package information. 
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Figure 4: Analytical determination of nicotine in the e-cigarette refills for which the 
nicotine content varies from 11 mg/ml to 18 mg/ml according to the package 
information. 
 
Figure 5: Analytical determination and fingerprint analysis of tobacco flavour in the e-
cigarette refills. 
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